No genetic predictors for response to glasdegib were identified so far; however, the presence of a DNMT3A mutation seems to negatively impact OS in patients with secondary AML and glasdegib + LDAC treatment [126]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.